Citations

Showing 10 of 108119 citations.

Magnetic Resonance Imaging During a Pandemic: Recommendations by the ISMRM Safety Committee
Collins, Jeremy D. , Rowley, Howard A. , Leiner, Tim , Hood, Maureen N. , Dekkers, Ilona A. , Gulani, Vikas , Kopanoğlu, Emre , Reeder, Scott B. , Dekkers, Ilona , Tha, Khin , Kopanoglu, Emre , Collins, Jeremy , Leiner, Tim

Mayo Clinic

Journal of Magnetic Resonance Imaging | December 20, 2021 | Volume: 55 | Issue: 5 | Pages: 1322-1339

10.1002/jmri.28006 | PMID 34927776 Get It

The COVID‐19 pandemic highlighted the challenges delivering face‐to‐face patient care across healthcare systems. In particular the COVID‐19 pandemic challenged the imaging community to provide timely access to essential diagnostic imaging modalities while ensuring appropriate safeguards were in place for both patients and personnel. With increasing vaccine availability and greater prevalence of vaccination in communities worldwide we are finally emerging on the other side of the COVID‐19 pandemic. As we learned from our institutional and healthcare system responses to the pandemic, maintaining timely access to MR imaging is essential. Radiologists and other imaging providers partnered with their referring providers to ensure that timely access to advanced MR imaging was maintained. On behalf of the International Magnetic Resonance in Medicine (ISMRM) Safety Committee, this white paper is intended to serve as a guide for radiology departments, imaging centers, and other imaging specialists who perform MR imaging to refer to as we prepare for the next pandemic. Lessons learned including strategies to triage and prioritize MR imaging research during a pandemic are discussed.Level of Evidence5Technical EfficacyStage 5
Diffuse Large B-Cell Lymphoma of Peripheral Nerve with Distinctive Pathological Features Resembling Primary CNS Lymphoma
Vizcaíno, M. Adelita , Kurtin, Paul J. , King, Rebecca L. , Spinner, Robert J. , Giannini, Caterina , Giannini, Caterina

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 20, 2021 | Volume: 81 | Issue: 1 | Pages: 76-78

10.1093/jnen/nlab117 | PMID 34927695 Get It

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura
Goadsby, Peter J. , Tepper, Stewart J. , Xue, Fei , Brennan, F. James, Lima, Gabriel Paiva da Silva , Goadsby, Peter J , Lima, Gabriel Paiva da Silva , Ashina, Messoud , Dodick, David W. , Zhang, Feng , Brennan, Francis

Mayo Clinic

JAMA Neurology | December 20, 2021 | Volume: 79 | Issue: 2 | Pages: 159

10.1001/jamaneurol.2021.4678 | PMID 34928306 Get It

De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability
Schalk, Audrey , Cousin, Margot A. , Dsouza, Nikita R., Challman, Thomas D. , Wain, Karen E. , Powis, Zöe , Minks, Kelly Q., Trimouille, Aurélien , Lasseaux, Eulalie , Michaud, Vincent , Van‐Gils, Julien , Spataro, Nino , Gabau, Elizabeth, Stolerman, Elliot , Washington, Camerun , Louie, Ray, Lanpher, Brendan C. , Kemppainen, Jennifer L., Innes, Micheil, Kooy, R. Frank , Goldenberg, Alice, Lecoquierre, François , Vera, Gabriella , Sheidley, Beth Rosen , Achkar, Christelle Moufawad El , Park, Meredith, Hamdan, Fadi F. , Michaud, Jacques L. , Lewis, Ann J., Zweier, Christiane , Wagner, Matias , Weigand, Heike, Journel, Hubert, Keren, Boris , Passemard, Sandrine , Mignot, Cyril , Brilstra, Eva H. , Itzikowitz, Gina, O’Heir, Emily , Allen, Jake, Donald, Kirsten A. , Korf, Bruce R. , Skelton, Tammi, Rudy, Natasha L. , Dobyns, William B. , Foss, Kimberly , Bosanko, Katherine A. , Alembik, Yves, Durand, Benjamin , Mau‐Them, Frédéric Tran , Ranza, Emmanuelle , Blanc, Xavier , Torti, Erin , Millan, Francisca , Dameron, Amy, Tokita, Mari, Zimmermann, Michael T. , Klee, Eric W. , Piton, Amélie , Gérard, Bénédicte , Ruiz, Anna , Stolerman, Elliot , Kooy, Frank , Lecoquierre, Francois , Reis, André , Wagner, Matias , Passemard, Sandrine , Tran Mau-Them, Frederic , Klee, Eric W , Piton, Amelie , Zimmermann, Michael T , Lacombe, Didier , Angelini, Chloé , Louie, Raymond J. , Meuwissen, Marije E. C. , Goldenberg, Alice , Diderich, Karin E. M. , Reis, André , Gassen, Koen L.I. van , Thompson, Michelle L. , Robin, Nathaniel H. , Zárate, Yuri A. , Antonarakis, Stylianos E. , McWalter, Kirsty

Mayo Clinic

Journal of Medical Genetics | December 20, 2021 | Volume: 59 | Issue: 10 | Pages: 965-975

10.1136/jmedgenet-2021-107751 | PMID 34930816 Get It

Background High-impact pathogenic variants in more than a thousand genes are involved in Mendelian forms of neurodevelopmental disorders (NDD). Methods This study describes the molecular and clinical characterisation of 28 probands with NDD harbouring heterozygous AGO1 coding variants, occurring de novo for all those whose transmission could have been verified (26/28). Results A total of 15 unique variants leading to amino acid changes or deletions were identified: 12 missense variants, two in-frame deletions of one codon, and one canonical splice variant leading to a deletion of two amino acid residues. Recurrently identified variants were present in several unrelated individuals: p.(Phe180del), p.(Leu190Pro), p.(Leu190Arg), p.(Gly199Ser), p.(Val254Ile) and p.(Glu376del). AGO1 encodes the Argonaute 1 protein, which functions in gene-silencing pathways mediated by small non-coding RNAs. Three-dimensional protein structure predictions suggest that these variants might alter the flexibility of the AGO1 linker domains, which likely would impair its function in mRNA processing. Affected individuals present with intellectual disability of varying severity, as well as speech and motor delay, autistic behaviour and additional behavioural manifestations. Conclusion Our study establishes that de novo coding variants in AGO1 are involved in a novel monogenic form of NDD, highly similar to the recently reported AGO2 -related NDD.
IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries
Corban, Michel T., Toya, Takumi , Albers, Diana, Sebaali, Faten, Lewis, B , Bois, John, Gulati, Rajiv , Prasad, Abhiram, Best, Patricia J.M., Bell, Malcolm R., Rihal, Charanjit S. , Prasad, Megha, Ahmad, Ali , Lerman, Lilach O. , Solseth, Mary L., Dietz, Allan B. , Lewis, Bradley R , Winters, Jeffrey L , Dietz, Allan B , Lerman, Amir , Toya, Takumi , Corban, Michel T., Albers, Diana, Sebaali, Faten, Bois, John, Gulati, Rajiv , Prasad, Abhiram, Best, Patricia J.M., Bell, Malcolm R., Rihal, Charanjit S. , Prasad, Megha, Ahmad, Ali , Lerman, Lilach O , Solseth, Mary L.

Mayo Clinic

Circulation Research | December 20, 2021 | Volume: 130 | Issue: 3 | Pages: 326-338

10.1161/circresaha.121.319644 | PMID 34923853 Get It

Background: Coronary endothelial dysfunction (CED) causes angina/ischemia in patients with nonobstructive coronary artery disease (NOCAD). Patients with CED have decreased number and function of CD34+ cells involved in normal vascular repair with microcirculatory regenerative potential and paracrine anti-inflammatory effects. We evaluated safety and potential efficacy of intracoronary autologous CD34+ cell therapy for CED. Methods: Twenty NOCAD patients with invasively diagnosed CED and persistent angina despite maximally tolerated medical therapy underwent baseline exercise stress test, GCSF (granulocyte colony stimulating factor)-mediated CD34+ cell mobilization, leukapheresis, and selective 1×10 5 CD34+ cells/kg infusion into left anterior descending. Invasive CED evaluation and exercise stress test were repeated 6 months after cell infusion. Primary end points were safety and effect of intracoronary autologous CD34+ cell therapy on CED at 6 months of follow-up. Secondary end points were change in Canadian Cardiovascular Society angina class, as-needed sublingual nitroglycerin use/day, Seattle Angina Questionnaire scores, and exercise time at 6 months. Change in CED was compared with that of 51 historic control NOCAD patients treated with maximally tolerated medical therapy alone. Results: Mean age was 52±13 years; 75% were women. No death, myocardial infarction, or stroke occurred. Intracoronary CD34+ cell infusion improved microvascular CED (%acetylcholine-mediated coronary blood flow increased from 7.2 [−18.0 to 32.4] to 57.6 [16.3–98.3]%; P =0.014), decreased Canadian Cardiovascular Society angina class (3.7±0.5 to 1.7±0.9, Wilcoxon signed-rank test, P =0.00018), and sublingual nitroglycerin use/day (1 [0.4–3.5] to 0 [0–1], Wilcoxon signed-rank test, P =0.00047), and improved all Seattle Angina Questionnaire scores with no significant change in exercise time at 6 months of follow-up. Historic control patients had no significant change in CED. Conclusions: A single intracoronary autologous CD34+ cell infusion was safe and may potentially be an effective disease-modifying therapy for microvascular CED in humans. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03471611.
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Csizmar, Clifford M. , Saliba, Antoine N. , Kaufmann, Scott H. , Saliba, Antoine N. , Kaufmann, Scott H , Saliba, Antoine N , Saliba, Antoine N , Csizmar, Clifford , Swisher, Elizabeth M.

Mayo Clinic

Cancers | December 20, 2021 | Volume: 13 | Issue: 24 | Pages: 6385

10.3390/cancers13246385 | PMID 34945003 Get It

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with conventional chemotherapy or the combination of a hypomethylating agent and venetoclax, de novo or acquired drug resistance often presents an insurmountable challenge, especially in older patients. Poly(ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2, are involved in detecting DNA damage and repairing it through multiple pathways, including base excision repair, single-strand break repair, and double-strand break repair. In the context of AML, PARP inhibitors (PARPi) could potentially exploit the frequently dysfunctional DNA repair pathways that, similar to deficiencies in homologous recombination in BRCA-mutant disease, set the stage for cell killing. PARPi appear to be especially effective in AML with certain gene rearrangements and molecular characteristics (RUNX1-RUNX1T1 and PML-RARA fusions, FLT3- and IDH1-mutated). In addition, PARPi can enhance the efficacy of other agents, particularly alkylating agents, TOP1 poisons, and hypomethylating agents, that induce lesions ordinarily repaired via PARP1-dependent mechanisms. Conversely, emerging reports suggest that long-term treatment with PARPi for solid tumors is associated with an increased incidence of myelodysplastic syndrome (MDS) and AML. Here, we (i) review the pre-clinical and clinical data on the role of PARPi, specifically olaparib, talazoparib, and veliparib, in aggressive myeloid neoplasms and (ii) discuss the reported risk of MDS/AML with PARPi, especially as the indications for PARPi use expand to include patients with potentially curable cancer.
Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality
Hinze, Alicia M. , Perin, Jamie , Woods, Adrianne, Wigley, Fredrick M. , Shah, Ami A. , Hinze, Alicia M , Hummers, Laura K , Mukherjee, Monica

Mayo Clinic

Arthritis & Rheumatology | December 20, 2021 | Volume: 74 | Issue: 5 | Pages: 849-859

10.1002/art.42054 | PMID 34927390 Get It

ObjectiveTo determine the independent risk factors for diastolic dysfunction (DD) in patients with systemic sclerosis (SSc) and to evaluate the impact of DD on mortality.MethodsSSc patients enrolled in the Johns Hopkins Scleroderma Center Cohort between November 1, 2006 and November 1, 2017 with ≥1 analyzable 2‐dimensional (2‐D) echocardiogram in our system were included (n = 806). DD risk factors and SSc disease characteristics were prospectively obtained, and the presence or absence of DD was determined using the most recent 2‐D echocardiogram. Logistic regression models examined associations between clinical risk factors and DD, and Cox proportional hazards models were used to assess survival.ResultsDD was present in 18.6% of participants. The majority of participants were female (84%) with a median age of 58.4 years (interquartile range 48.8–68.1). Older age (odds ratio [OR] 1.12 [95% confidence interval (95% CI) 1.09–1.15], P < 0.001), coronary artery disease (OR 3.69 [95% CI 1.52–8.97], P = 0.004), obesity (OR 4.74 [95% CI 2.57–8.74], P < 0.001), longer SSc disease duration (OR 1.04 [95% CI 1.01–1.06], P = 0.004), diffusing capacity for carbon monoxide ≤60% of predicted (OR 2.41 [95% CI 1.40–4.16], P = 0.002), and history of scleroderma renal crisis (OR 3.18 [95% CI 1.12–9.07], P = 0.031) were all independently associated with an increased risk of DD. Anti–Scl‐70 positivity (OR 0.49 [95% CI 0.26–0.93], P = 0.03) and severe gastrointestinal disease (OR 0.48 [95% CI 0.30–0.79], P = 0.004) were associated with a reduced risk of DD. The presence of DD was independently associated with an increase in the risk of mortality (hazard ratio 1.69 [95% CI 1.07–2.68], P = 0.027).ConclusionDD is independently associated with an increased risk of mortality in patients with SSc. Potentially modifiable risk factors, including coronary artery disease and obesity, should be addressed in patients with SSc to reduce mortality risk.
Pain mechanisms in carpal tunnel syndrome: a systematic review and meta-analysis of quantitative sensory testing outcomes
Sobeeh, Mohamed Gomaa , Ghozy, Sherief , Elshazli, Rami M. , Landry, Marc , Sobeeh, Mohamed G , Ghozy, Sherief

Mayo Clinic

Pain | December 20, 2021 | Volume: 163 | Issue: 10 | Pages: e1054-e1094

10.1097/j.pain.0000000000002566 | PMID 35050958 Get It

Abstract Carpal tunnel syndrome (CTS) is the most common nerve compression in the arm. A mix of peripheral and central contributions on quantitative sensory testing (QST) has been reported in the literature. Thus, this systematic review or meta-analysis aimed to identify the dominant sensory phenotype and draw conclusive evidence about the presence of central sensitization (CS) in CTS. Based on an a priori published protocol and using PRISMA guidelines, 7 databases were searched (Embase, Web of Science, Scopus, PubMed, SAGE, EBSCOhost, and ProQuest). Eligible studies compared the QST findings of individuals with subacute and chronic CTS with those of healthy controls through thermal, mechanical, and vibration detection thresholds; thermal, pressure, and mechanical pain thresholds; mechanical pain sensitivity; presence of allodynia; wind-up ratio; and conditioned pain modulation. Thirty-seven studies were included in the qualitative analysis. Results showed a significant loss of all detection thresholds of hand median nerve territories and hand extramedian areas (little finger and hand dorsum) in CTS (P < 0.05) but no significant difference (P > 0.05) in wind-up ratio, cold, heat, or mechanical pain thresholds of the median nerve territories. Furthermore, there was a significant increase in mechanical pain sensitivity in median nerve territories and remotely in the forearm (P < 0.05) and a significant gain in pressure and heat pain thresholds in the carpal area (P < 0.05). Conditioned pain modulation was impaired in CTS. Hypoesthesia and increased thermal and mechanical pain ratings are the dominant sensory phenotype with inconclusive evidence about CS in CTS due to the heterogenous results of thermal and mechanical pain thresholds.
Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception
Martin, Laurent , Ibrahim, Mohab , Gómez, Kimberly , Yu, Jie , Chew, Lindsey A. , Bellampalli, Shreya S. , Moutal, Aubin , Largent‐Milnes, Tally M. , Porreca, Frank , Patwardhan, Amol , Cai, Song , Chew, Lindsey A , Largent-Milnes, Tally, Khanna, Rajesh , Olivera, Baldomero M , Patwardhan, Amol , Martin, Laurent , Khanna, Rajesh , Olivera, Baldomero M.

Mayo Clinic

Pain | December 20, 2021 | Volume: 163 | Issue: 9 | Pages: 1751-1762

10.1097/j.pain.0000000000002561 | PMID 35050960 Get It

Abstract Intrathecal application of contulakin-G (CGX), a conotoxin peptide and a neurotensin analogue, has been demonstrated to be safe and potentially analgesic in humans. However, the mechanism of action for CGX analgesia is unknown. We hypothesized that spinal application of CGX produces antinociception through activation of the presynaptic neurotensin receptor (NTSR)2. In this study, we assessed the mechanisms of CGX antinociception in rodent models of inflammatory and neuropathic pain. Intrathecal administration of CGX, dose dependently, inhibited thermal and mechanical hypersensitivities in rodents of both sexes. Pharmacological and clustered regularly interspaced short palindromic repeats/Cas9 editing of NTSR2 reversed CGX-induced antinociception without affecting morphine analgesia. Electrophysiological and gene editing approaches demonstrated that CGX inhibition was dependent on the R-type voltage-gated calcium channel (Cav2.3) in sensory neurons. Anatomical studies demonstrated coexpression of NTSR2 and Cav2.3 in dorsal root ganglion neurons. Finally, synaptic fractionation and slice electrophysiology recordings confirmed a predominantly presynaptic effect. Together, these data reveal a nonopioid pathway engaged by a human-tested drug to produce antinociception.
Corticosteroid Injections After Rotator Cuff Repair Improve Function, Reduce Pain, and Are Safe: A Systematic Review
Puzzitiello, Richard N. , Patel, Bhavik H. , Lavoie‐Gagne, Ophelie , Nwachukwu, Benedict U. , Lu, Yining , Forsythe, Brian , Salzler, Matthew J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | December 20, 2021 | Volume: 4 | Issue: 2 | Pages: No page available

10.1016/j.asmr.2021.10.010 | PMID 35494258 Get It

Purpose To review the literature on postoperative corticosteroid injections (CSIs) following primary rotator cuff repair (RCR) to evaluate efficacy and adverse effects. Methods A systematic review of the MEDLINE, EMBASE, and Cochrane databases were performed to identify all studies published within the last 15 years, which reported on outcomes of postoperative CSIs following RCR. Studies including patients who received only preoperative CSIs and revision RCRs were excluded. Included studies were evaluated for study methodology, patient demographics, outcome measures, physical examination parameters, results of imaging studies, and adverse effects or clinical complications. Results Seven studies comprising 5,528 patients satisfied inclusion criteria. Among included patients, 54.8% were female and mean age range from 52.3 ± 13.0 to 62.7 ± 6.6 years. Only 1 included investigation was a Level I study. Overall, 4 of 5 studies reported significant improvements in pain and outcome scores (Constant score, American Shoulder and Elbow Surgeons score) compared with controls. Across all studies, the majority of these effects were statistically significant at 3 months postoperatively but not beyond this time point. Five of the 6 included investigations reported no increased rate of retears after postoperative CSIs. One study did find an increase in retear in patients receiving postoperative CSIs but was unable to determine whether these retears were present before the patient received the CSI. Another investigation reported an increased rate of infection only if the CSI was administered in the first postoperative month. Conclusions Postoperative CSIs may improve pain and function for up to 3 months following primary RCR but not at later follow‐up time points. CSIs should be administered only after the first postoperative month to minimize the potential risk for adverse events. Level of Evidence Systematic review of level I‐IV studies.